Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes

NCT00605475 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

231

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Canakinumab
DRUG: Placebo
DRUG: Metformin

Sponsor

Novartis